Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
P-IL-2 + anti-PD-1 monoclonal antibody (Zhejiang University)
- Development stage
- Unknown
- Lead developer
- Zhejiang University
- Modality
- Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
P-IL-2 + anti-PD-1 monoclonal antibody is an investigational combination immunotherapy being developed by Zhejiang University for the treatment of advanced solid tumors. The combination consists of P-IL-2, a novel cell-based therapy where Interleukin-2 (IL-2) is coupled to platelets, and an anti-PD-1 monoclonal antibody. P-IL-2 is designed to leverage the natural tumor-homing and activation properties of platelets to deliver IL-2 directly to the tumor microenvironment, potentially enhancing anti-tumor efficacy while reducing the systemic toxicities (such as vascular leak syndrome) associated with high-dose IL-2. The anti-PD-1 antibody acts as a checkpoint inhibitor, blocking the PD-1/PD-L1 pathway to restore T-cell mediated anti-tumor immunity. This combination is currently being evaluated in a Phase 1 clinical trial for various advanced malignancies, including esophageal, bladder, liver, ovarian, and small cell lung cancers.
- Other names
- Platelet-coupled IL-2 + anti-PD-1 monoclonal antibodyP-IL-2 plus Anti-PD-1 Monoclonal AntibodyP-IL2 plus Anti-PD-1 Monoclonal AntibodyP-IL 2 plus Anti-PD-1 Monoclonal Antibody
Beyond the preview
Go deeper on P-IL-2 + anti-PD-1 monoclonal antibody (Zhejiang University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on P-IL-2 + anti-PD-1 monoclonal antibody (Zhejiang University).